All trials View full record on ClinicalTrials.gov
NCT05231785PHASE1RECRUITING
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
✨ Plain-English version on the way · ~2 days
We're still translating this one. In a couple of days, you'll see what this trial actually tests — and whether it matters for APOE4 carriers like you. For now, here's the sponsor's own description:
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose and multiple doses of ALN-APP administered by intrathecal (IT) injection in adult patients with early-onset Alzheimer's Disease (EOAD). Maximum treatment duration for Part A: single dose. Maximum treatment duration for Part B: 12 months.Read full record on ClinicalTrials.gov
Eligibility check — Phoenix members
Phoenix members see for THIS trial:
- APOE genotype match
- Cognitive status fits inclusion
- Specific exclusions flagged
- Distance to nearest site
Sites
8 locations
Start
2022-02-04
Interventions tested
- DRUGALN-APP
- DRUGPlacebo